Modalis Therapeutics Corporation

Modalis Therapeutics Corporation is a biotechnology company focused on research and development of therapeutics for serious genetic disorders. It uses its proprietary CRISPR-GNDM epigenome editing technology, which combines dCas9, to develop therapies for genetic diseases. Its pipeline also includes therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. Formerly known as EdiGENE Corporation, it changed its name to Modalis Therapeutics Corporation in August 2019, was incorporated in 2016, and is headquartered in Chuo, Japan.